Gwyneth Astles NEWSASIA Bringing you all the latest News and Views from the Science Industry Environmental
Education Programme in India Expanded
Gyros and DI Biotech Sign Distribution Agreement for the Korean Market
Gyros®
AB, a leading provider of automated micro-immunoassays for therapeutic protein development, is pleased to announce the signing of a distribution agreement with DI Biotech, a leading supplier to the Korean life-science market. Under the terms of the agreement, DI Biotech will market and provide full support for Gyros’ proprietary technology, Gyrolab®
, to the Korean pharmaceutical, biotech, CRO and
CMO industries. Gyrolab has rapidly become established as a preferred technology for high-performance immunoassays for the development of biotherapeutics. The technology is increasingly employed by leading pharmaceutical and biotech companies, and their contracted service organisations, in their drug development process and clinical trials, in both Europe and the USA. As a result of this success, the company has now decided to expand its business into Asia, with Korea as its initial market.
Wang Rong Wen (Clariant), Dr Helmut Berg (Bayer Technology Services) and Michael Ziesemer (Endress+Hauser) in discussion during the NAMUR conference.
The first ‘NAMUR comes to China’ conference has met with a great deal of interest. The aim of these activities is to set up a process automation network in the Asian region. The keynote event on 19/20 November in Shanghai was sponsored by Endress+Hauser China. More and more member businesses of NAMUR – an international user association of automation technology in process industries – operate successfully in Asia. Other stakeholders to be addressed include users in Chinese process engineering firms. “In the Asian region in general and in China in particular, immense production capacities have been built over the past years,” said Michael Ziesemer, Chief Operating Officer (COO) of the Endress+Hauser Group. “There is a definite need for exchange of information. Sponsoring the first ‘NAMUR comes to China’ conference is our way of showing our support for setting up this network.”
Dr Yu Guangjian, Managing Director of Endress+Hauser China, welcomes NAMUR’s move to Asia. “This is a much better way of satisfying the needs of the businesses working here and of getting to know the special cultural features,” stated Dr Yu. The conference has been scheduled to follow the NAMUR Annual General Meeting. In addition to technical questions, issues involving safety, security and environmental protection were the subject of intensive discussions in Shanghai. Endress+Hauser contributed to the ‘NAMUR comes to China’ conference with its own technical lectures focusing on the field of liquid analysis.
TO FIND OUT MORE CIRCLE NO. 306
“We are very happy to have DI Biotech representing our products in the Korean market”, states Erik Walldén, CEO and President of Gyros. “It’s an organisation with longstanding experience, presence, and a solid position as a leading supplier of high-tech tools to the biotech market. S. E. Kim, CEO and President at DI Biotech comments: “We have already tested the market for Gyrolab in Korea, and the response was immediate and positive, which was very encouraging. The benefits that Gyrolab provides are recognised in all sectors of pharmaceutical development, as well as in government-funded institutes. Pharma, biotech and especially, the fast-growing CRO and CMO companies, all see possibilities, to not only ramp-up productivity, but also to boost their competitiveness. The financial standing of these industries was already strong, and coupled with the Korean government’s recent investment of the equivalent of 90 million EUR, to further propel the development of biotherapeutics within the ‘SMART project’, we are extremely optimistic about the rapid uptake and implementation of Gyrolab in Korea.”
TO FIND OUT MORE CIRCLE NO. Sartorius Opens New Plant in India
In a ribbon-cutting ceremony Sartorius inaugurated its new plant at the Sartorius Group’s location in Bangalore, India. Together with some 100 guests from the scientific community and politics, CEO Dr Joachim Kreuzburg, Supervisory Board Chairman Professor Arnold Picot and MD of Sartorius India Amit Chatterjee officially started up operations at the large building complex covering 10,000 square meters. At its new site, Sartorius has combined its five decentralised individual locations in Bangalore into a single
new plant on premises comprising an area of 40,000 square meters or 430,560 square feet, thus creating new capacity for the company’s fast-growing Indian business in both Group divisions. Among other products, Sartorius in Bangalore, India, develops and manufactures bioreactors and additional equipment for pharmaceutical customers, lab equipment as well scales and other weighing equipment for industrial applications. The Sartorius Group invested approximately 5 million euros in the new plant complex.
In his address to the attendees, Dr Kreuzburg stated that for over two decades Sartorius has built up a strong position in India with respect to its local and global customers from the biotech, pharmaceutical and food sectors. Following its German sites with some 2,220 employees, Sartorius India, with its staff numbering nearly 500 members, now has the second-largest workforce within the entire Sartorius Group. “I am especially delighted that despite the impact of the financial and economic crisis, we can propel the further development of our business in India forward with our new plant,“ said Dr Kreuzburg. Dr Kreuzburg continued, “Many of our international key accounts are increasingly expanding their production and research facilities in India and are manufacturing products there in compliance with international standards.
TO FIND OUT MORE CIRCLE NO. Dr Yousoo Kim Wins the 2009 Sir Martin Wood Prize
The 2009 "Millennium Science Forum" organised by Oxford Instruments was held at the British Embassy in Tokyo on Wednesday 11th November 2009. The Millennium Science Forum was established in 1998 to promote scientific exchange between the UK and Japan and award prizes to young researcher from a Japanese University or research institute who have performed outstanding research in the area of condensed matter science. The prize is named after Sir Martin Wood, Founder and Honorary President of Oxford Instruments plc.
Professor Hidetoshi Fukuyama from Tokyo University of Science chairs the Sir Martin Wood prize selection committee and 7 senior Professors from Japanese Universities sit on the committee. The Sir Martin Wood Prize winner receives ¥500,000 in cash and the opportunity to give a series of lectures in UK Universities. The winner of the 2009 "Sir Martin Wood Prize" Is Dr Yousoo Kim from The surface Chemistry Laboratory in Riken. Dr Kim was awarded the prize for the study of local electronic structure and electron-stimulated reaction of a single molecule at surface and following the prize ceremony at the Millennium Science Forum, Dr Kim will give a lecture on his research.
307 305
At the table: Professor Sanjay Mittal, (Dean of Academic Affairs, IITK), Professor Christine Ennew (University of Nottingham), Janat Shah (IIMB)
New entrepreneurial opportunities in the pharmaceutical and biotechnology industries have opened up between India and the UK with the signing of a £1.5m UK-India Science Bridge, Biopharm 2020. The three-year grant has been funded by The Research Councils UK (RCUK) and Department of Science and Technology (DST) India and was officially launched at the India Habitat Centre in New Delhi. Experts from The University of Nottingham, the Indian Institute of Management, Bangalore and the Indian Institute of Technology, Kanpur aim to create a step- change in collaborative innovation in target identification, drug discovery, drug delivery and manufacturing. They will build on existing collaborations with the goal of producing clinical and commercial benefits from patent protected research. Professor Kevin Shakesheff, Professor of Advanced Drug Delivery at The University of Nottingham, said: “World changing advances in pharmaceuticals and regenerative medicine will require large collaborative teams to work towards common goals. BioPharm 2020 brings together leading research groups with industry. The teams at Nottingham, Kanpur and Bangalore have very different skills and by combining our ideas we can undertake new challenges that will advance us far beyond that achievable within the smaller individual groups.”
Dr Yousoo Kim receiving his award from Mr David Warren, British Ambassador to Japan
TO FIND OUT MORE CIRCLE NO. 308
Director IITKanpur, Professor Sanjay Govind Dhande, said: "I am very pleased to note the progress with UK-India Science Bridge initiative. I would like to congratulate the participating researchers on the occasion of the official launch of the Science Bridge. It is also a major landmark in our effort to bring about Industry-Academia linkages. “Our collaboration with The University of Nottingham and Indian Institute of Management Bangalore would provide the right impetus for us to achieve leadership in translational Biomedical research. I also express my gratitude to the funding agencies, DST and RCUK, for supporting this venture. I wish a grand success for the UK-India Science Bridge.” The three partners will build on extensive collaborations with the goals of producing: clinical and commercial benefits from patent protected research; a world class human resource with a focus on interfacing with Industry; and an assessment of the supply chain and outsourcing potential for long-term business engagement and policy formulation between the two countries.
TO FIND OUT MORE CIRCLE NO. 309
NEWSASIA NEWSASIA NEWSASIA NEWSASIA
UK and India to Build ‘Science Bridges’
Page 1 |
Page 2 |
Page 3 |
Page 4 |
Page 5 |
Page 6 |
Page 7 |
Page 8 |
Page 9 |
Page 10 |
Page 11 |
Page 12 |
Page 13 |
Page 14 |
Page 15 |
Page 16 |
Page 17 |
Page 18 |
Page 19 |
Page 20 |
Page 21 |
Page 22 |
Page 23 |
Page 24 |
Page 25 |
Page 26 |
Page 27 |
Page 28 |
Page 29 |
Page 30 |
Page 31 |
Page 32 |
Page 33 |
Page 34 |
Page 35 |
Page 36 |
Page 37 |
Page 38 |
Page 39 |
Page 40 |
Page 41 |
Page 42 |
Page 43 |
Page 44 |
Page 45 |
Page 46 |
Page 47 |
Page 48 |
Page 49 |
Page 50 |
Page 51 |
Page 52 |
Page 53 |
Page 54 |
Page 55 |
Page 56
